PDCD1 and melanoma: When combining ipilimumab with PD-1 inhibitors like nivolumab in melanoma, drug-related adverse events of grade 3 or 4 were reported in 53% of patients compared with 18% of patients who received ipilimumab monotherapy72,81,.82